Medicenna Therapeutics
Medicenna Therapeutics
MDNA
TSX
1.09
CAD
0.93%
About
Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company's principal business activity is the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases.
Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM).
The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program Targeted Metalloprotease Activated SuperKine (T-MASK) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 45.3K |
| Three Month Average Volume | 2.0M |
| High Low | |
| Fifty-Two Week High | 2.98 CAD |
| Fifty-Two Week Low | 0.215 CAD |
| Fifty-Two Week High Date | 03 Jun 2024 |
| Fifty-Two Week Low Date | 01 Nov 2023 |
| Price and Volume | |
| Current Price | 2.46 CAD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | 3.63% |
| Thirteen Week Relative Price Change | -17.67% |
| Twenty-Six Week Relative Price Change | 92.46% |
| Fifty-Two Week Relative Price Change | 319.26% |
| Year-to-Date Relative Price Change | 425.81% |
| Price Change | |
| One Day Price Change | 12.84% |
| Thirteen Week Price Change | -13.68% |
| Twenty-Six Week Price Change | 108.47% |
| Five Day Price Change | 14.42% |
| Fifty-Two Week Price Change | 382.35% |
| Year-to-Date Price Change | 485.71% |
| Month-to-Date Price Change | 15.49% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.07454 CAD |
| Book Value Per Share (Most Recent Quarter) | 0.29936 CAD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.07372 CAD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.29864 CAD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.25832 CAD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 CAD |
| Revenue Per Share (Trailing Twelve Months) | 0 CAD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 CAD |
| Dividend Per Share (Trailing Twelve Months) | 0 CAD |
| Dividend Per Share (5 Year) | -99999.99 CAD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.36569 CAD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.37399 CAD |
| Normalized (Last Fiscal Year) | -0.36569 CAD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.36569 CAD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.37399 CAD |
| Including Extraordinary Items (Last Fiscal Year) | -0.36569 CAD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.37399 CAD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.24386 CAD |
| Cash Per Share (Most Recent Quarter) | 0.46615 CAD |
| Cash Flow Per Share (Last Fiscal Year) | -0.36562 CAD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.37138 CAD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.2145 CAD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -4.03% |
| Tangible Book Value (5 Year) | 15.16% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -20.19% |
| EPS Change (Trailing Twelve Months) | -194.43% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 37 |
| Price to Tangible Book (Most Recent Quarter) | 8 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -35,629,000 |
| Net Debt (Last Fiscal Year) | -16,982,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 33 |
| Price to Book (Most Recent Quarter) | 8 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 7 |
| Current Ratio (Most Recent Quarter) | 9 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -16,260,000 |
| Free Cash Flow (Trailing Twelve Months) | -15,151,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -3 |
| Net Interest Coverage (Trailing Twelve Months) | -2 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -91.64% |
| Return on Assets (Trailing Twelve Months) | -75.44% |
| Return on Assets (5 Year) | -54.93% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -146.88% |
| Return on Equity (Trailing Twelve Months) | -105.43% |
| Return on Equity (5 Year) | -65.09% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -104.12% |
| Return on Investment (Trailing Twelve Months) | -84.22% |
| Return on Investment (5 Year) | -60.91% |